I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 4 studies | 27% ± 12% | |
| non-classical monocyte | 3 studies | 21% ± 2% | |
| epithelial cell | 3 studies | 26% ± 1% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 4 studies | 27% ± 12% | |
| non-classical monocyte | 3 studies | 21% ± 2% | |
| epithelial cell | 3 studies | 26% ± 1% |
Insufficient scRNA-seq data for expression of RNFT1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 472.48 | 1445 / 1445 | 100% | 11.96 | 183 / 183 |
| breast | 100% | 865.39 | 459 / 459 | 100% | 12.47 | 1116 / 1118 |
| lung | 100% | 740.20 | 577 / 578 | 100% | 11.63 | 1153 / 1155 |
| bladder | 100% | 503.24 | 21 / 21 | 99% | 10.30 | 499 / 504 |
| thymus | 100% | 745.03 | 653 / 653 | 99% | 10.13 | 597 / 605 |
| ovary | 100% | 696.07 | 180 / 180 | 98% | 7.20 | 423 / 430 |
| stomach | 100% | 487.27 | 358 / 359 | 99% | 10.76 | 282 / 286 |
| prostate | 100% | 516.05 | 245 / 245 | 98% | 7.17 | 491 / 502 |
| intestine | 100% | 689.42 | 966 / 966 | 97% | 9.17 | 513 / 527 |
| liver | 100% | 777.59 | 226 / 226 | 97% | 9.01 | 394 / 406 |
| pancreas | 100% | 615.26 | 328 / 328 | 97% | 6.75 | 172 / 178 |
| uterus | 99% | 458.79 | 169 / 170 | 97% | 9.55 | 446 / 459 |
| brain | 96% | 342.07 | 2541 / 2642 | 99% | 8.18 | 701 / 705 |
| skin | 100% | 580.01 | 1804 / 1809 | 93% | 9.38 | 438 / 472 |
| kidney | 100% | 374.49 | 89 / 89 | 92% | 7.57 | 829 / 901 |
| adrenal gland | 100% | 956.15 | 258 / 258 | 90% | 4.90 | 208 / 230 |
| adipose | 100% | 888.25 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 9.91 | 29 / 29 |
| spleen | 100% | 840.19 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 6.54 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 2.57 | 1 / 1 |
| muscle | 100% | 575.09 | 802 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 99% | 449.03 | 1328 / 1335 | 0% | 0 | 0 / 0 |
| heart | 97% | 377.82 | 833 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 87% | 380.22 | 804 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 81% | 5.81 | 65 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0051865 | Biological process | protein autoubiquitination |
| GO_1904294 | Biological process | positive regulation of ERAD pathway |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0061630 | Molecular function | ubiquitin protein ligase activity |
| GO_0043130 | Molecular function | ubiquitin binding |
| GO_0046872 | Molecular function | metal ion binding |
| Gene name | RNFT1 |
| Protein name | RING-type E3 ubiquitin transferase (EC 2.3.2.27) E3 ubiquitin-protein ligase RNFT1 (EC 2.3.2.27) (Protein PTD016) (RING finger and transmembrane domain-containing protein 1) Ring finger protein, transmembrane 1 |
| Synonyms | PTD016 |
| Description | FUNCTION: E3 ubiquitin-protein ligase that acts in the endoplasmic reticulum (ER)-associated degradation (ERAD) pathway, which targets misfolded proteins that accumulate in the endoplasmic reticulum (ER) for ubiquitination and subsequent proteasome-mediated degradation. Protects cells from ER stress-induced apoptosis. . |
| Accessions | K7EJ18 ENST00000482446.5 [Q5M7Z0-3] ENST00000484257.1 E9PI44 ENST00000466544.5 ENST00000305783.13 [Q5M7Z0-1] Q5M7Z0 H0YEZ8 ENST00000589113.1 |
